Literature DB >> 6371972

Human lymphocyte function-associated antigens.

A M Krensky, F Sanchez-Madrid, T A Springer, S J Burakoff.   

Abstract

Three cell surface molecules, designated LFA-1, LFA-2, and LFA-3 were identified by mAbs selected for their ability to block cytolysis by an OKT4+, HLA-DR-specific CTL line. The LFA mAbs block all CTL and proliferative functions studied. In addition, anti-LFA-1 mAbs inhibit NK-mediated cytolysis. By analogy with murine LFA-1, human LFA-1 may be involved in the adhesion stage of cellular interactions. LFA-2, the SRBC receptor molecule, appears to be a T cell function-specific molecule. We have not yet established whether LFA-2 participates in antigen recognition or whether it is involved in antigen-non-specific interactions. The anti-LFA-3 mAb specifically blocks function by binding to the target cells, implying that LFA-3 may be a target ligand for an effector-specific receptor. The CTL-target interaction involves a number of steps, including antigen recognition, cell adhesion, and delivery of the lethal hit [22]. The LFA antigens show the complexity of this process at the molecular level. The anti-LFA monoclonal antibodies will be useful probes into the T cell immune response and may prove clinically relevant, both diagnostically and therapeutically.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6371972     DOI: 10.1007/bf02918596

Source DB:  PubMed          Journal:  Surv Immunol Res        ISSN: 0252-9564


  22 in total

1.  Identification and functional characterization of two distinct epitopes on the human T cell surface protein Tp50.

Authors:  P J Martin; G Longton; J A Ledbetter; W Newman; M P Braun; P G Beatty; J A Hansen
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

Review 2.  Lymphoid cell surface interaction structures detected using cytolysis-inhibiting monoclonal antibodies.

Authors:  P Golstein; C Goridis; A M Schmitt-Verhulst; B Hayot; A Pierres; A van Agthoven; Y Kaufmann; Z Eshhar; M Pierres
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

3.  A novel lymphocyte function-associated antigen (LFA-1): cellular distribution, quantitative expression, and structure.

Authors:  K Kürzinger; T Reynolds; R N Germain; D Davignon; E Martz; T A Springer
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

Review 4.  Mechanism of specific tumor-cell lysis by alloimmune T lymphocytes: resolution and characterization of discrete steps in the cellular interaction.

Authors:  E Martz
Journal:  Contemp Top Immunobiol       Date:  1977

5.  Antibody directed at a surface structure inhibits cytolytic but not suppressor function of human T lymphocytes.

Authors:  E L Reinherz; R E Hussey; K Fitzgerald; P Snow; C Terhorst; S F Schlossman
Journal:  Nature       Date:  1981-11-12       Impact factor: 49.962

6.  Clonal analysis of human cytotoxic T lymphocytes: T4+ and T8+ effector T cells recognize products of different major histocompatibility complex regions.

Authors:  S C Meuer; S F Schlossman; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

7.  Antigens involved in mouse cytolytic T-lymphocyte (CTL)-mediated killing: functional screening and topographic relationship.

Authors:  F Sanchez-Madrid; D Davignon; E Martz; T A Springer
Journal:  Cell Immunol       Date:  1982-10       Impact factor: 4.868

Review 8.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.

Authors:  J C Cerottini; K T Brunner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

9.  Inhibition of specific cell-mediated cytotoxicity by monoclonal antibodies to human T cell antigens.

Authors:  C D Platsoucas; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

Review 10.  LFA-1 and Lyt-2,3, molecules associated with T lymphocyte-mediated killing; and Mac-1, an LFA-1 homologue associated with complement receptor function.

Authors:  T A Springer; D Davignon; M K Ho; K Kürzinger; E Martz; F Sanchez-Madrid
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.